PhI/II of JIN-A02 in Patients w/ EGFR Mutant Adv NSCLC

Cancer
Misako Nagasaka
A Phase I/II, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Lung

Study Description

Eligibility

  • Subjects age 18 or above (19 or above for South Korea)
  • Subjects with pathologically confirmed and finally diagnosed advanced and/or metastatic NSCLC with active EGFR mutant
  • Subjects who show disease progression after receiving approved standard EGFR-TKI therapies, including Osimertinib or Lazertinib, a third-generation EGFR-TKI. Platinum-based anticancer chemotherapy is allowed up to 1 time after using EGFR-TKI treatment
  • Subjects with known sensitivity to the study drug or its related substance
  • Subjects who have a history of drug abuse or unstable medical, mental or social conditions that may interfere with participation in the study or result interpretation
  • Subjects considered not able to follow the protocol as determined by the investigator
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.